Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 11/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 11/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.42 |
| ▸ | LMNA | P02545 | 7/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 9/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6976721 | 0.85 | CLK4 (0.43) | CYP3A4CLK4CYP1A2LMNACYP2C9 | |
| SCHEMBL6959473 | 0.85 | CYP3A4 (0.43) | CYP3A4CLK4CYP1A2LMNACYP2C9 | |
| SCHEMBL496982 | 0.80 | CSNK2A1 (0.51) | ALDH1A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29894777 | 0.80 | CSNK2A1 (0.51) | ALDH1A1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL28806345 | 0.78 | SLC2A1 (0.53) | CYP3A4CLK4CYP1A2LMNACYP2C9 | |
| SCHEMBL5191348 | 0.76 | PDE4A (0.47) | HSD17B10ALDH1A1TSHRPDE4APDE4B | |
| SCHEMBL17025587 | 0.76 | KDM4E (0.39) | CYP3A4CLK4CYP1A2LMNACYP2C9 | |
| SCHEMBL1680503 | 0.74 | ALDH1A1 (0.56) | CYP1A2LMNACYP2C9HSD17B10ALDH1A1 | |
| SCHEMBL1644909 | 0.74 | POLB (0.56) | CYP3A4CYP1A2LMNACYP2C9ALDH1A1 | |
| SCHEMBL3707249 | 0.74 | HPGD (0.43) | CYP3A4HSD17B10ALDH1A1TSHRENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1854789-B1 | QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-1854789-A1 | QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | CYP3A4 1985/4885CLK4 625/4885CYP1A2 1375/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | CYP3A4 1985/4885CLK4 625/4885CYP1A2 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.